[18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results

详细信息    查看全文

• 作者：Francesco Pasqualetti ; Marco Panichi ; Aldo Sainato…
• 关键词：Choline PET/CT ; Stereotactic body radiotherapy ; Oligometastatic patients ; Recurrent prostate cancer
• 刊名：Radiation Oncology
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：11
• 期：1
• 全文大小：539 KB
• 参考文献：1.Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRef PubMed
  2.Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.CrossRef PubMed
  3.Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403. Research Support, Non-U.S. Gov’t.CrossRef PubMed
  4.Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–79. Practice Guideline Review.CrossRef PubMed
  5.Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004;171(3):1141–7. Comparative Study Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.CrossRef PubMed
  6.Giovacchini G, Picchio M, Briganti A, Cozzarini C, Scattoni V, Salonia A, et al. [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J Urol. 2010;184(3):938–43.CrossRef PubMed
  7.Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37(2):301–9.CrossRef PubMed
  8.Fuccio C, Castellucci P, Schiavina R, Guidalotti PL, Gavaruzzi G, Montini GC, et al. Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. Eur J Radiol. 2012;81(8):e893–6.CrossRef PubMed
  9.Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. Editorial.PubMed
  10.Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14(1):e28–37. Research Support, Non-U.S. Gov’t Review.CrossRef PubMed
  11.Conde Moreno AJ, Ferrer Albiach C, Muelas Soria R, Gonzalez Vidal V, Garcia Gomez R, Albert Antequera M. Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options. Radiat Oncol. 2014;9:258. Research Support, Non-U.S. Gov’t.CrossRef PubMed
  12.Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N, et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer. 2013;11(1):27–32.CrossRef PubMed
  13.Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol. 2011;60(5):935–43.CrossRef PubMed
  14.Decaestecker K, De Meerleer G, Lambert B, Delrue L, Fonteyne V, Claeys T, et al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol. 2014;9:135.PubMedCentral CrossRef PubMed
  15.Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: A systematic review of the literature. Eur Urol. 2015;67(5):852–63. Review.CrossRef PubMed
  16.Ahmed KA, Barney BM, Macdonald OK, Miller RC, Garces YI, Laack NN, et al. Stereotactic body radiotherapy in the treatment of adrenal metastases. Am J Clin Oncol. 2013;36(5):509–13.CrossRef PubMed
  17.Greco C, Zelefsky MJ, Lovelock M, Fuks Z, Hunt M, Rosenzweig K, et al. Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. Int J Radiat Oncol Biol Phys. 2011;79(4):1151–7. Clinical Trial, Phase I.CrossRef PubMed
  18.Zelefsky MJ, Greco C, Motzer R, Magsanoc JM, Pei X, Lovelock M, et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2012;82(5):1744–8. Clinical Trial, Phase I.PubMedCentral CrossRef PubMed
  19.Wilson MK, Collyar D, Chingos DT, Friedlander M, Ho TW, Karakasis K, et al. Outcomes and endpoints in cancer trials: bridging the divide. Lancet Oncol. 2015;16(1):e43–52. Review.CrossRef PubMed
  20.Wilson MK, Karakasis K, Oza AM. Outcomes and endpoints in trials of cancer treatment: the past, present, and future. Lancet Oncol. 2015;16(1):e32–42. Historical Article Review.CrossRef PubMed
  21.Schweizer MT, Zhou XC, Wang H, Yang T, Shaukat F, Partin AW, et al. Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol. 2013;24(11):2881–6. Clinical Trial Research Support, N.I.H., Extramural.PubMedCentral CrossRef PubMed
  22.Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37(8):4078–101.CrossRef PubMed
  23.de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54. Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t.CrossRef PubMed
  24.Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12. Clinical Trial Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t.CrossRef PubMed
  25.Tilki D, Reich O, Graser A, Hacker M, Silchinger J, Becker AJ, et al. 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol. 2013;63(5):792–6. Evaluation Studies.CrossRef PubMed
  
• 作者单位：Francesco Pasqualetti (1) (9)
  Marco Panichi (1)
  Aldo Sainato (1)
  Fabrizio Matteucci (1)
  Luca Galli (2)
  Paola Cocuzza (1)
  Patrizia Ferrazza (1)
  Gabriele Coraggio (1)
  Giuseppe Pasqualetti (3)
  Lisa Derosa (2)
  Martina Sollini (3)
  Lorenzo Mannelli (5)
  Simona Ortori (6)
  Fabio Monzani (4)
  Sergio Ricci (2)
  Carlo Greco (7)
  Maria Grazia Fabrini (1)
  Paola Anna Erba (8)
  
  1. Radiation Oncology, Azienda Ospedaliero Universitaria Pisana, Via Roma 55, 56126, Pisa, Italy
  9. Radiation Oncology, Pisa University Hospital, Via Roma 67, 56126, Pisa, Italy
  2. Medical Oncology, Azienda Ospedaliero Universitaria Pisana, Via Roma 55, 56126, Pisa, Italy
  3. Humanitas University, Via Manzoni 113, Rozzano, Milano, 20089, Italy
  5. Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
  6. Radiology, Azienda Ospedaliero Universitaria Pisana, Via Roma 55, 56126, Pisa, Italy
  4. Geriatrics Unit, Azienda Ospedaliero Universitaria Pisana, Via Roma 55, 56126, Pisa, Italy
  7. Radiation Oncology, Champalimaud Centre for the Unknown, Avenida Brasília, 1400-038, Lisboa, Portugal
  8. Department of Translational Research and New Technologies in Medicine, Regional Center of Nuclear Medicine, University of Pisa, Via Savi 10, 56126, Pisa, Italy
  
• 刊物主题：Oncology; Radiotherapy;
• 出版者：BioMed Central
• ISSN：1748-717X

文摘

Background A new entity of patients with recurrent prostate cancer limited to a small number of active metastatic lesions is having growing interest: the oligometastatic patients. Patients with oligometastatic disease could eventually be managed by treating all the active lesions with local therapy, i.e. either surgery or ablative stereotactic body radiotherapy. This study aims to assess the impact of [18F]Choline ([18F]FMCH) PET/CT and the use stereotactic body radiotherapy (SBRT) in patients (pts) with oligometastatic prostate cancer (PCa).